The immediate aim is to identify which trial options should be checked with the specialist and research team before treatment begins.
Ticks save automatically as the discussion progresses.
Start with the first two groups. Then use the later and lower-priority groups if the higher-priority options are not suitable or become relevant later.
Important: The priority order is a research and appointment-preparation tool. It does not establish eligibility, predict benefit or replace the specialist's assessment.
Whichever centre calls back first, here's what's confirmed, and what to say when they pick up.
“I have [diagnosis], and I'd like a second opinion and to understand if I'm eligible for any clinical trials before treatment starts.”
“Given my planned treatment start date, can you see me urgently, within the week if possible?”
“If I wait for a second opinion, does that put my current treatment start date at risk, or can they run in parallel?”
“Has my tumour had molecular testing — KRAS, BRCA, others — and if not, can you arrange the quickly using my existing biopsy tissue?”
“Do you offer a liquid biopsy blood test that could be faster than a new tissue sample?”
“Based on my diagnosis and staging, what trials would I realistically be eligible for, here or elsewhere in the UK?”
“Does starting chemo now rule any trials out later, or can they run alongside it?”
“Can you liaise directly with my current oncology team for my scans, pathology and notes?”
“What's the likely cost for an urgent consultation, and separately for biomarker testing if needed?”
For the appointment itself. Ask about all of it — not to have all of it. Cast the net wide and let the specialist do the filtering.
Ticks save automatically as you go.
↑ Back to topPrioritised review: 37 trials matching the accompanying PDF. The list is grouped into First Priority (1–10), Second Priority (11–15), Later or Conditional (16–29), and Lower Priority (30–37). The numbered order is the discussion order from the accompanying PDF.
† Conditional means that eligibility may depend on a biomarker, tumour biology, disease pattern, treatment history or timing, or another trial-specific requirement that cannot be confirmed here and needs confirmation from the specialist or research team.
The main list is ordered by the priority groups in the accompanying PDF. The filter buttons below sort by trial type, not by eligibility or medical recommendation.
Potential cancer treatment — an interventional treatment study where the intervention is intended to treat the existing cancer. Cancer treatment — specific circumstances — a treatment study that may be relevant, but the card identifies a material circumstance that needs specialist checking (for example tumour subtype, biomarker, treatment timing or disease pattern). Not a cancer-treatment trial — the study itself is not intended to treat the existing cancer, even if it is interventional.Search the live registry using the same kind of free-text terms you would use on ClinicalTrials.gov — drug names, trial codes, biomarkers, cancer types, NCT numbers or combinations of terms.
Tip: try the exact drug/code first, then broader combinations if you get no useful results. ClinicalTrials.gov supports Boolean searches such as KRAS AND pancreatic.
More targeted or personalised treatment, potentially available to start soon, without standard chemotherapy. Whether the side-effect profile is preferable needs to be discussed with the specialist.
Registry name: PemOla — pembrolizumab + olaparib
What to ask: Ask whether I am eligible now and whether starting my planned treatment would affect eligibility.
Type: Advanced/metastatic Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: DETERMINE — trastuzumab + pertuzumab
What to ask: Ask whether my tumour has a qualifying HER2 change.
Type: Molecular/biomarker Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: BAY 3713372
What to ask: Ask whether my tumour has an MTAP deletion and whether the trial is available in the UK.
Type: Molecular/biomarker Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: OligoRARE — SBRT
What to ask: Ask whether my pattern of spread is considered oligometastatic and whether the trial is relevant.
Type: Oligometastatic Phase: Phase 3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: YntraDose
What to ask: Ask whether my cancer is locally advanced and whether this study is still open to people like me.
Type: Locally advanced Phase: Early phase
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: AMG 410
What to ask: Ask whether my tumour has the relevant KRAS alteration and whether the pancreatic cohort is open.
Type: Molecular/biomarker Phase: Early phase
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: NEXUS-01 — LY4052031
What to ask: Ask whether my tumour has the relevant characteristics and whether my previous treatment meets the study rules.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: GSK5764227 / EMBOLD PanGI-201
What to ask: Ask whether pancreatic cancer is included in the currently open part of the study.
Type: Advanced/metastatic Phase: Early phase
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: MGC026
What to ask: Ask the specialist/research team to check the pancreatic cohort and treatment-history requirements.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: PF-08046054 / SGN-PDL1V
What to ask: Ask whether the pancreatic cohort is open and whether I meet its specific criteria.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusThe same priority as above, but with chemotherapy included. This includes ASPIRE, which uses gemcitabine + nab-paclitaxel alongside an experimental drug.
Registry name: Telisotuzumab adizutecan + FOLFOX (AndroMETa-PDAC-288)
What to ask: Ask whether I could enter before starting my planned treatment. The current record lists a UK recruiting site in Oxford.
Type: Advanced/metastatic Phase: Phase 2/3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: ASPIRE — SBP-101 + gemcitabine/nab-paclitaxel
What to ask: Ask whether this is an option given my planned gemcitabine + nab-paclitaxel treatment.
Type: Advanced/metastatic Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: SGN-CEACAM5C / PF-08046050
What to ask: Ask whether pancreatic cancer is an active cohort and what the eligibility requirements are.
Type: Advanced/metastatic Phase: Early phase
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: ENACT — Acoustic Cluster Therapy
What to ask: Ask whether my disease is classified as locally advanced and whether this trial could apply.
Type: Locally advanced Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: ART0380
What to ask: Ask whether the pancreatic-cancer part of the study is relevant to me.
Type: Advanced/metastatic Phase: Phase 1/2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusOptions that may become more relevant after treatment, or if testing shows a particular feature in the cancer.
Registry name: BNT329
What to ask: Ask whether my tumour expresses CA19-9 and whether this trial is realistic for me.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: HER3-DXd
What to ask: Ask whether the pancreatic cohort is open and whether my treatment history fits.
Type: Advanced/metastatic Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: UCB4594
What to ask: Ask whether the pancreatic-cancer cohort is recruiting and whether my previous/current treatment matters.
Type: Advanced/metastatic Phase: Phase 1/2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: HTL0039732
What to ask: Ask whether the pancreatic group is appropriate for me and whether my previous treatment affects eligibility.
Type: Advanced/metastatic Phase: Phase 1/2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: MK-2870 (MK-9999-02A)
What to ask: Ask whether this pancreatic-cancer cohort could fit my situation and whether it affects my current treatment plan.
Type: Advanced/metastatic Phase: Phase 2/3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: AZD5863
What to ask: Ask whether the pancreatic cohort is open and whether I meet the study rules.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: OKN4395 + pembrolizumab (INVOKE)
What to ask: Ask whether the pancreatic cohort is open and what the eligibility requirements are.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: GTAEXS617 / ELUCIDATE
What to ask: Ask the research team whether pancreatic cancer is currently included and whether I fit.
Type: Advanced/metastatic Phase: Phase 1/2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: AZD9574 / CERTIS1
What to ask: Ask whether the pancreatic group is relevant and what previous treatment is allowed.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: MOMA-313
What to ask: Ask whether the pancreatic group is open and whether I meet its criteria.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: Sigvotatug Vedotin (SGN-B6A)
What to ask: Ask whether the pancreatic cohort is currently open and whether I fit.
Type: Advanced/metastatic Phase: Early phase
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: WEF-001
What to ask: Ask whether my tumour has the required KRAS change.
Type: Molecular/biomarker Phase: Phase 1/2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: APL-101 / SPARTA
What to ask: Ask whether my tumour has the required mutation and whether pancreatic cancer is currently recruiting.
Type: Molecular/biomarker Phase: Early phase
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: INBRX-109
What to ask: Ask whether there is a pancreatic-cancer cohort and whether it is open in the UK.
Type: Advanced/metastatic Phase: Phase 1
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusTrials that are less closely matched to the current situation, while remaining visible so that potentially useful information is not lost.
Registry name: TT-702 / CURATE
What to ask: Ask the research team to confirm whether pancreatic cancer is an active cohort.
Type: Advanced/metastatic Phase: Interventional
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: Belzutifan (MK-6482-015)
What to ask: Only relevant if my tumour is a pancreatic neuroendocrine tumour or meets another study-specific condition.
Type: Neuroendocrine Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: CAREFNDR — paltusotine
What to ask: Only relevant if I have the relevant neuroendocrine tumour and carcinoid syndrome.
Type: Neuroendocrine Phase: Phase 2
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: STELLAR-311 — zanzalintinib vs everolimus
What to ask: Only relevant if my tumour is a pancreatic neuroendocrine tumour.
Type: Neuroendocrine Phase: Phase 3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: NETTER-3
What to ask: Only relevant if my tumour is a relevant neuroendocrine tumour.
Type: Neuroendocrine Phase: Phase 3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: IMCODE003
What to ask: Relevant to people who have had surgery and are receiving treatment afterwards.
Type: Post-surgery/adjuvant Phase: Phase 2/3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: RASolute 304 — daraxonrasib after surgery
What to ask: Relevant only to the postoperative situation described by the study.
Type: Post-surgery/adjuvant Phase: Phase 3
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusRegistry name: RASolute 303 — daraxonrasib + gemcitabine/nab-paclitaxel
What to ask: Could I be eligible for RASolute 303, and would starting my planned gemcitabine + nab-paclitaxel treatment affect that?
Type: Advanced/metastatic Phase: Phase 3
Source: Identified separately from the Pancreatic Cancer UK finder. This is not a Pancreatic Cancer UK endorsement. The current official record lists recruiting sites in the US and Japan, so UK availability needs to be checked separately.
↗ ClinicalTrials.gov — official trial record, eligibility criteria and current recruitment statusThis is a working, local feature — it does not use AI. It compares the information you enter with the structured trial information already in this guide and ranks the trials that share the most relevant signals.
The matcher looks at several answers together — cancer type, current situation, treatment history and biomarker/genomic information — rather than treating one matching word as enough. It gives more weight to stronger signals and shows the specific signals that contributed to each result.
Important: a stronger match does not mean a person is eligible. Trial criteria can include details that are not represented in this simple local matcher, and the official record and research team remain the source of truth.
These are research prompts, not eligibility decisions. Location is a practical signal only; site recruitment and eligibility must be checked on the official record. The ranking explains why a trial surfaced; it does not estimate the probability of being accepted onto it.
Pinned trials stay on this device, even after you refresh the page. They are a shortlist, not a statement of eligibility.
The local matcher can keep improving by using the structured information already in the guide: weighting multiple answers together, distinguishing strong signals from missing information, and explaining exactly why a trial appeared. That keeps it instant, private and dependable without needing an AI service.
Use the local matcher first, then ask AI to help you make sense of the search. You can describe the situation in ordinary language, ask what information is missing, or ask which of the surfaced trials are most worth discussing with the research team.
This is the detailed research behind the things worth discussing with a specialist. You do not need to read every card.
Important: This is promising research, but it does not mean it will work for me or that I can receive it now. A specialist needs to check whether there is a suitable trial or treatment route.